Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbvic Inc.

Abbvie Ireland Unlimited Company

Sven Mensing

Sandeep Dutta

Walid M Awni

Barry M Bernstein

Thomas J Podsadecki

Rajeev M Menon

Cheri E Klein

Daniel E Cohen

Amit Khatri

Scott C Brun

Emily O Dumas

Wei Liu

Chih-Wei Lin

Tianli Wang

Andrew L Campbell

John Hayslip

Leanne M Holes

Silpa Nuthalapati

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Methods for treating HCV

The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.

Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Method for treating HCV

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Growing community of inventors

Mannheim, Germany

Sven Mensing